l e t t e r s
Recombinant glycoprotein therapeutics produced in nonhuman mammalian cell lines and/or with animal serum are often modified with the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc; refs. 1,2). This documented contamination has generally been ignored in drug development because healthy individuals were not thought to react to Neu5Gc (ref. 2) . However, recent findings indicate that all humans have Neu5Gc-specific antibodies, sometimes at high levels 3, 4 . Working with two monoclonal antibodies in clinical use, we demonstrate the presence of covalently bound Neu5Gc in cetuximab (Erbitux) but not panitumumab (Vectibix). Anti-Neu5Gc antibodies from healthy humans interact with cetuximab in a Neu5Gc-specific manner and generate immune complexes in vitro. Mice with a human-like defect in Neu5Gc synthesis generate antibodies to Neu5Gc after injection with cetuximab, and circulating anti-Neu5Gc antibodies can promote drug clearance. Finally, we show that the Neu5Gc content of cultured human and nonhuman cell lines and their secreted glycoproteins can be reduced by adding a human sialic acid to the culture medium. Our findings may be relevant to improving the half-life, efficacy and immunogenicity of glycoprotein therapeutics.
Therapeutic glycoproteins, including antibodies, growth factors, cytokines, hormones and clotting factors, generate sales with annual double-digit growth rates 5 . They must often be produced in mammalian expression systems because of the crucial influence of the location, number and structure of N-glycans on their yields, bioactivity, solubility, stability against proteolysis, immunogenicity and rate of clearance from the bloodstream [6] [7] [8] .
Two differences between the protein glycosylation apparatus of humans and rodents account for major potential differences between the N-glycans on glycoproteins made in cultured human cells and those made using rodent cell lines. First, humans cannot synthesize a terminal Galα1-3Gal motif (known as alpha-Gal) on N-glycans. As a consequence, they express antibodies against this structure 9 . Second, unlike other mammals, humans cannot biosynthesize the sialic acid Neu5Gc because the human gene CMAH, encoding CMP-N-acetylneuraminic acid hydroxylase, the enzyme responsible for producing CMP-Neu5Gc from CMP-N-acetylneuraminic acid (CMP-Neu5Ac), is irreversibly mutated 10 . The use of cultured human cells to address this issue is not a solution, as Neu5Gc can be taken up from animal products present in the culture medium and then metabolically incorporated into secreted glycoproteins 11 .
Owing largely to limitations of the assays originally used to detect anti-Neu5Gc antibodies, including the fact that only a small number of possible Neu5Gc-containing epitopes were tested, healthy humans were long believed to show no immune reaction to Neu5Gc (ref. 2) . Subsequent reports that all humans possess anti-Neu5Gc antibodies 3 , sometimes at high levels, approaching 0.1-0.2% of circulating IgG 3, 4 , have led to re-evaluation of the potential significance of Neu5Gc contamination 7, 8 . Especially in light of trends toward administering increasingly higher amounts of certain biotherapeutics over longer periods of time, some biopharmaceutical companies are exploring steps to reduce levels of Neu5Gc in their products 12 .
Given that they are produced using nonhuman cell lines, animal serum or serum-derived factors, or a combination of these, it is likely that most recombinant therapeutic glycoproteins carry some Neu5Gc. However, given the diversity of products and production protocols, it is difficult to make generalizations. Thus, we chose to compare two US Food and Drug Administration (FDA)-approved monoclonal antibodies with the same therapeutic target, the EGF receptor. The first, Erbitux (cetuximab, obtained from the University of California, San Diego Pharmacy), is a chimeric antibody produced in mouse myeloma cells 13, 14 . The second, Vectibix (panitumumab, obtained from Amgen), is a fully human antibody produced in Chinese hamster ovary (CHO) cells 15 . The samples studied were preparations that would normally be administered to patients.
We first performed enzyme-linked immunosorbent assays (ELISAs) using an affinity-purified polyclonal chicken Neu5Gc-specific antibody preparation that is highly monospecific for Neu5Gc (ref. 16 , alongside a nonreactive control IgY). Bound Neu5Gc was easily detectable on cetuximab but not on panitumumab (Fig. 1a) . Sialidase pretreatment abolished binding, confirming specificity. Western blot analysis also showed sialidase-sensitive anti-Neu5Gc IgY reactivity on the heavy chains of cetuximab but not those of panitumumab (Fig. 1b) . The specificity of anti-Neu5Gc IgY binding was reaffirmed by pretreatment with mild sodium periodate under conditions that selectively cleave sialic acid side chains (Fig. 1c) and abolish reactivity of such antibodies 3, 16 . Finally, we quantified sialic acids on the therapeutic antibodies, as described in Online Methods. Panitumumab carries 0.22 mol of sialic acids per mole of protein, with <0.1% Neu5Gc. Tables 2 and 3 for a listing of other potential examples). Pull-down assays of cetuximab with SNA-agarose (modified with the lectin Sambucus nigra agglutinin, which recognizes α2-6-linked sialic acids), followed by ELISAs of unbound proteins, showed that only about half of cetuximab molecules actually carry bound sialic acids and Neu5Gc (data not shown). Such heterogeneity is typical for glycoproteins.
To address the potential significance of the high levels of antiNeu5Gc antibodies found in certain humans, we affinity purified antiNeu5Gc antibodies from normal human sera and biotinylated them exactly as previously described 4 , before their analysis using ELISA and western blotting assays (Fig. 1d,e) . As with Neu5Gc-specific chicken IgY, these affinity-purified human Neu5Gc-specific antibodies reacted with cetuximab but not with panitumumab. Again, reactivity was abrogated by pretreatment with mild sodium periodate (Fig. 1d) or sialidase (Fig. 1e) .
To further address potential clinical relevance, we studied whether addition of cetuximab to normal human sera is capable of promoting the formation of immune complexes (Fig. 1f) . Cetuximab formed immune complexes in a human serum with high levels of anti-Neu5Gc antibodies (serum S34; ref. 4) but not in a low-titer serum (serum S30; ref. 4) . In contrast, we detected no formation of immune complexes with either serum in the presence of panitumumab. Assuming that similar interactions occur between cetuximab and circulating antiNeu5Gc antibodies in humans, these complexes could potentially fix complement and cause untoward reactions in some patients and/or affect half-life, possibly explaining some reported clinical differences between cetuximab and panitumumab 13, 15 ,
We next evaluated whether Neu5Gc affects clearance rate when circulating anti-Neu5Gc antibodies are present. To mimic the situation in humans, we used mice with a human-like defect in the Cmah gene, which encodes the enzyme that generates activated Neu5Gc (CMP-Neu5Gc) 18 . Such mice can make anti-Neu5Gc antibodies upon immunization with glycosidically bound, but not free, Neu5Gc [19] [20] [21] . However, the previous studies reporting these mouse anti-Neu5Gc antibodies used whole rodent or chimpanzee cells for immunization 19, 20 , an artificial approach. In contrast, feeding of Neu5Gc (which is present in mouse chow) does not induce a human-like immune response in the mutant mice 21 . We could not immunize the mice with cetuximab itself, as other antibodies directed against the partly human IgG protein backbone would confound any results. To most closely mimic the situation in humans, we therefore immunized with Neu5Gc-loaded Haemophilus influenzae (see Online Methods and ref. 21 ; this is very similar to the mechanism by which human Neu5Gc-specific antibodies appear to be generated naturally 21 ). Given the great variability in isotypes and affinities of the naturally occurring human anti-Neu5Gc antibodies, as well as their different relative reactivities against various Neu5Gc-containing antigens 4 , it is impractical to model all possible human conditions. We therefore chose to mimic a situation in a human with relatively high levels of the IgG antibodies against the kind of Neu5Gc epitope (Neu5Gcα2-6Galβ1-4Glc-) found in cetuximab 22 . It also happens that this epitope is commonly recognized by human anti-Neu5Gc antibodies 4 .
Each of the therapeutic antibodies, cetuximab and panitumumab, was injected intravenously at levels estimated to ensure a concentration of 1 μg ml −1 in the extracellular fluid volume according to mouse body weight 23 . Next, sera pooled from naïve, control-immunized or Neu5Gc-immunized syngeneic mice were passively transferred via intraperitoneal injection, ensuring equal starting concentrations of circulating Neu5Gc-specific antibodies. Anti-Neu5Gc IgG levels in the pooled sera from Neu5Gc-immunized mice were quantified using ELISA with a Neu5Gcα2-6Galβ1-4Glc-conjugate as a target, as previously described 4 (97.5 μg ml −1 , data not shown). The amount of pooled antibody injected was then calculated to achieve an approximate In an additional ELISA, Cet and Pan were used for coating, then blocked, and sialic acid epitopes were modified chemically using mild sodium metaperiodate pretreatment. The reaction was stopped using sodium borohydride. As a control, periodate and borohydride were mixed and then added to the wells (the borohydride inactivates the periodate). ELISA samples were studied at least in triplicate and data shown are means ± s.d. ***P < 0.001, paired two-tailed t-test. (d) Cet and Pan were pretreated with mild periodate as in c and used to coat ELISA wells before blocking and incubation with human anti-Neu5Gc IgG that had been purified from the serum of healthy humans and biotinylated as previously described 4 . Samples were studied in triplicate and data shown are means ± s.d. ***P < 0.001, paired two-tailed t-test. (e) Cet and Pan (1 μg each) were treated with sialidase or heat-inactivated sialidase as in a separated by SDS-PAGE, Coomassie-stained, blotted (see b), and Neu5Gc detected using biotinylated human anti-Neu5Gc IgG. (f) Immune complex formation with Cet or Pan in whole human serum was detected using the CIC (C1Q) ELISA Kit (Buehlmann) as described in the manufacturer's guidelines. Absorbance was measured at 405 nm. Samples were studied in triplicate and data shown are means ± s.d. **P < 0.01, paired two-tailed t-test. Gels in b and e were cropped for clarity of presentation. Full-length blots and gels are presented in Supplementary Figures 1-4 . l e t t e r s starting concentration of 4 μg ml −1 IgG in the extracellular fluid volumes of the mice, which is about a four fold excess of anti-Neu5Gc antibodies compared to the injected drug in the mice, and similar to levels found in some humans 4 .
Clearance was monitored by a sandwich ELISA specific for human IgG-Fc. Although both drugs had a similar clearance rate in mice pre-injected with serum from naïve or control-immunized mice, circulating levels of cetuximab decreased significantly (P < 0.001) when Neu5Gc-specific antibodies were pre-injected (Fig. 2a) . Assuming that a similar interaction between cetuximab and circulating anti-Neu5Gc antibodies occurs in patients, there could be relevant effects on clearance rate and efficacy. This might help to explain the wide range of half-life values reported for such antibodies in clinical studies 14, 15 .
To further simulate the clinical situation, we injected equal amounts of cetuximab or panitumumab intravenously into Neu5Gc-deficient Cmah −/− mice in typical human dosages (4 μg per gram of body weight) at weekly intervals. To exclude any effect of the human portion of the protein (cetuximab) or of the fully human protein (panitumumab) in mice, we also injected murine IgG as a positive control, as it happens to carry Neu5Gc as the predominant sialic acid (Supplementary Table 1) . Notably, cetuximab and murine IgG (but never panitumumab) induced a Neu5Gc-specific IgG immune response (Fig. 2b) . As with humans, responses of individual mice varied greatly, and more positive signals were obtained with the Neu5Gc epitope mixture found in chimp serum than that in bovine fibrinogen. Thus, even patients without pre-existing high levels of anti-Neu5Gc antibodies may be at risk of developing them after injection of Neu5Gc-carrying agents, potentially affecting the outcome of subsequent injections. Moreover, repeated injections of Neu5Gc-carrying agents could result in the accumulation of this nonhuman sugar in human tissues. Together with Neu5Gc-specific antibodies, accumulation of Neu5Gc in tissues can mediate chronic inflammation and potentially facilitate progression of diseases such as cancer 19 and atherosclerosis 24 . Thus, chronic use of Neu5Gc-bearing therapeutics might increase future risk of such diseases.
Finally, we studied direct binding of anti-Neu5Gc antibodies from whole human sera to both cetuximab and panitumumab. To avoid excessive cross-reactivity involving the secondary reagent, we prepared Fab fragments of both of the agents, used them to coat ELISA plate wells, exposed them to human sera and then detected serum antibody binding with a human IgG-Fc-specific secondary antibody (note that cetuximab is known to have an additional glycosylation site in the V-region 21 ). We detected mild periodate-sensitive binding of serum IgG from a high-anti-Neu5Gc titer serum (S34, ref. 4), which had >15 μg ml −1 IgG antibodies against Neu5Gcα2-6Galβ1-4Glc-) to the Fab fragments of cetuximab and not to those of panitumumab (Fig. 2c) . In contrast, incubation with another human serum containing very low Neu5Gc-antibodies (serum S30, ref. 4 , which had <2 μg ml −1 IgG antibodies against Neu5Gcα2-6Galβ1-4Glc-) did not show much periodate-sensitive binding (Fig. 2c) . Thus, whole human sera with high (but not low) titers of anti-Neu5Gc antibodies showed sialic acid-dependent (mild periodate-sensitive) binding of serum IgG to cetuximab but not to panitumumab.
Assuming that our in vitro and in vivo data translate into clinically relevant difficulties for some patients given Neu5Gc-containing biotherapeutics, how can one prevent this problem? Even biotherapeutics produced in human cell lines can be contaminated with Neu5Gc incorporated from animal-derived culture medium materials. Furthermore, it is difficult to change from the well-established and FDA-approved cell lines currently in use. Also, Neu5Gc in cells is 'recycled' in lysosomes and reused 11 . We hypothesized that free N-acetylneuraminic acid (Neu5Ac) in the medium would be taken up and compete with pre-existing Neu5Gc, preventing such recycling. Also, excess Neu5Ac would compete with any further incorporation of medium Neu5Gc (ref. 11). We therefore preloaded human 293T cells with Neu5Gc and then chased this with a culture medium with or without 5 mM Neu5Ac. Exposure to Neu5Ac indeed resulted in more rapid disappearance of both ethanol-precipitable (glycosidically bound) and ethanol-soluble (free) Neu5Gc from the human cells (Fig. 3a,b) . Thus, addition of Neu5Ac to the medium is a simple and nontoxic way to eliminate or reduce Neu5Gc contamination of human cells, which are now being used in the production of biotherapeutic agents-for example, Xigris from Eli Lilly and Elaprase from Shire Pharmaceuticals.
Given the considerable number of recombinant biotherapeutic glycoproteins currently produced in nonhuman cells and the presence of Figure 2 Effects of Neu5Gc-specific antibodies on the kinetics of therapeutic antibodies in mice with a human-like Neu5Gc deficiency, levels of anti-Neu5Gc IgG in mice after injections of the therapeutic antibodies, and binding of IgG Neu5Gc-specific antibodies from whole human serum to Neu5Gc on the Fab fragment of cetuximab. (a) Cmahnull mice were first injected intravenously with either of the therapeutic antibodies, cetuximab (Cet) or panitumumab (Pan). Serum from Cmah-null mice containing anti-Neu5Gc antibodies (or serum from naïve mice or control-immunized mice) was then passively transferred by intraperitoneal injection. Mice were bled periodically after the passive transfer of serum. Concentrations of Cet or Pan in the isolated sera were determined by sandwich ELISA. Absorbance was measured at 495 nm. The y axis starts at 60% to better display the difference in kinetics. Error bars, s.d.; ***P < 0.001, unpaired two-tailed t-test. (b) Cmah-null mice were injected intravenously with Cet, Pan or mouse IgG weekly and were bled initially and after the third intravenous injection. To detect Neu5Gc-specific antibodies by ELISA, we coated wells with human (Neu5Gc-deficient) or chimpanzee (Neu5Gc-positive) serum glycoproteins (upper chart), or alternatively with human or bovine fibrinogen (lower chart). Data were obtained in triplicate. (c) Fab fragments of Cet and Pan were isolated using the Pierce Fab Preparation Kit according to the manufacturer's manual for use as target molecules in ELISA (1 μg per well). Sialic acid-specific binding was determined using mild sodium metaperiodate pretreatment. Wells were then blocked and incubated with human sera (S30 and S34, with low and high anti-Neu5Gc IgG titers, respectively 4 ). Binding of human IgG was detected using anti-human IgG-Fc. Absorbance was measured at 490 nm and ELISA samples were studied in triplicate. Error bars, s.d.; *P < 0.05, paired two-tailed t-test. l e t t e r s small amounts of Neu5Gc in recombinant glycoproteins produced in CHO cells 1,16 , we next asked whether feeding Neu5Ac could reduce total glycoprotein Neu5Gc levels in CHO cells. This was successful for all membrane glycoproteins and for a secreted recombinant protein ( Fig. 3c-e) . Similar feeding of murine myeloma cells with Neu5Ac did not substantially reduce the higher initial Neu5Gc content (~70-80% of sialic acids), most probably because of the higher baseline levels of Cmah in these cells. Regardless, given that the CHO cell expresses its own Cmah enzyme, these data suggest a novel mechanism, in addition to Neu5Ac competing out recycled Neu5Gc. Whatever that mechanism, reduction of Neu5Gc content of a recombinant glycoprotein can be achieved even in a nonhuman Cmah-positive cell line that starts with low levels of Neu5Gc. Despite their successful use for a variety of indications, infusionrelated reactions, immunogenicity and accelerated clearance remain important concerns for many therapeutic glycoproteins 7, 25 . The incidence and severity of an immune reaction depends on the interplay of infused agents with the immune system and can vary greatly from patient to patient. Understanding the underlying nature of these events will help to identify patients at risk with the use of specific markers. Humanized and fully human antibodies have been developed to reduce immunogenicity due to peptide epitopes 5 . However, the potential immunogenicity of the glycans they carry has not been as well considered. It is known that immune reactions can be mediated by binding of pre-existing IgEs against the nonhuman alpha-Gal epitope carried by some agents, such as cetuximab 13 . However, in our studies alpha-Gal residues are not an issue, as Cmah-null mice already express this sequence and do not have antibodies against it.
A further concern arises here because pre-existing antibodies against a glycan on a glycoprotein can secondarily enhance antibody reactivity against the underlying protein backbone 26 , perhaps because immune complexes are cleared efficiently by Fc receptors into dendritic cells and other antigen-presenting cells 27, 28 . Such a mechanism might help explain why patients' immunogenicity to some glycoprotein therapeutics sometimes increases over time 26, 29, 30 . If this were true, it would likely have a further impact in long-term replacement therapy with recombinant therapeutic glycoproteins.
Our findings suggest that the potential significance of the presence of Neu5Gc on glycoprotein biotherapeutics should be revisited. Despite a natural tendency to downplay potential new problems involving currently useful drugs, it is worthwhile to consider lessons from other fields, where initial enthusiasm was not balanced by full appreciation of immunological implications 31 . With this in mind, we have also suggested that Neu5Gc contamination of stem cells and other cell types intended for human therapy could pose risks 32, 33 . In addition, others have recently reported that Cmah-null mice can reject Neu5Gc-positive wild-type organ transplants via complement-fixing Neu5Gc-specific antibodies 20 .
For new drugs, it may be possible to avoid Neu5Gc contamination from the outset by using Neu5Gc-deficient cells and media. Meanwhile, as an immediate practical solution, we have also demonstrated a nontoxic way to reduce the Neu5Gc content of some currently used expression systems and their secreted glycoproteins, by simply adding Neu5Ac to the culture media. This could bypass the need to establish new Neu5Gc-deficient cell lines for already approved drugs. The addition of Neu5Ac to the media could also potentially increase total sialylation of a glycoprotein biotherapeutic agent. But if anything, such an increase would only be beneficial-for example, leading to a longer half-life of the agent in vivo.
METHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. . The individually collected medium was centrifuged to remove cell debris and adjusted to 5 mM Tris-HCl pH 8. The fusion protein was purified using protein A-Sepharose, and sialic acid content was determined by DMB-HPLC analysis as described in Online Methods (c). Total cell membranes from the same CHO cells were prepared and used for DMB-HPLC analysis (d). CHO membrane proteins from d were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Expression of Neu5Gc (e) was detected by incubating with polyclonal affinity-purified chicken anti-Neu5Gc IgY, as described in Online Methods.
